Navigation Links
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Date:4/22/2010

NEW YORK, LONDON and HAMILTON, Bermuda, April 22 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the initiation of a Phase I/II pediatric dose tolerance trial to test their investigational new drug XERECEPT® in pediatric patients suffering from primary, recurrent or metastatic brain tumors.

Celtic Pharma's objective for this trial is to rapidly demonstrate the tolerability to increasing doses of XERECEPT® in pediatric patients.  Upon identification of the maximum tolerated dose, the study will continue to investigate the clinical benefits of XERECEPT® in this population, particularly with regard to reduction of dexamethasone dosing requirements and concomitant clinical benefit to the patients.  Dr. Stewart Goldman, medical director of the Neuro-Oncology unit at Northwestern University's Feinberg School of Medicine and the study's Principal Investigator commented, "I am excited to be working on this very important trial.  The effects of dexamethasone dosing on these children who have brain tumors is heart wrenching and I look forward to working with Celtic Pharma in the testing of XERECEPT® in these patients."

Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma further commented, "The current standards of care and prognosis for pediatric patients with brain tumors is very poor and we believe that XERECEPT® may provide a welcome and needed treatment for these children, in whom the effects of high-dose steroids are so devastating.  We have been in close contact with leading pediatric neuro-oncologists and look forward to the completion of this trial. This study is an important el
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
4. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
7. Who Is The Next-Generation Pharmacist(TM)?
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
11. NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... Talyst, a market leader in pharmacy automation, ... State Veterans Homes (NASVH) Summer Conference in ... NASVH is to ensure that each and every eligible ... care and respect which they have earned by their ... Remote Dispensing System, Talyst can help State Veterans Homes ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., ... company that develops, manufactures and sells patented biopharmaceutical, ... pharmaceuticals, today announced that the senior management will ... quarter of fiscal year 2011 ending September 30, ...
... Md., Nov. 8, 2010 Substandard and counterfeit versions ... locations across Ghana by the Medicines Quality Monitoring surveillance ... Board (FDB) in collaboration with the U.S. Pharmacopeial Convention ... the program samples antimalarials across the public and private ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3
(Date:7/24/2014)... Members of the Iowa State Board of Health ... of Sales at OutcomesMTM, as their Chairperson. Wolnerman said he ... and that his peers chose to keep him in this ... I can for the citizens of Iowa,” Wolnerman said. “As ... a special insight to concerns and issues related to the ...
(Date:7/24/2014)... BOSTON -- A new study has shown that it is ... by measuring the short-term effects of that same exposure. The ... , will make it possible to develop simpler and cheaper ... , Despite an overall decrease in incidence of ... be diagnosed with the disease in their lifetime, and around ...
(Date:7/24/2014)... PHILADELPHAA rare procedure occasionally performed during Jewish circumcisions that ... herpes simplex virus type 1 (HSV-1) transmissions documented ... review conducted by Penn Medicine researchers and published ... Disease Society found. The reviewers, from Penn,s ... cases in New York, Canada and Israel. , The ...
(Date:7/24/2014)... the Human Papillomavirus Vaccination (HPV) even after becoming ... test results than those who were never vaccinated. ... Transmitted Diseases . , Researchers from Boston ... Medicine conducted a cross-sectional study of 235 women ... testing. HPV status and demographic and behavioral characteristics ...
(Date:7/24/2014)... According to market research report "3D ... Forecasts and Analysis - 2018", the 3D mapping ... $7.7 billion by 2018 at a CAGR of ... data tables and 30 figures spread through 222 ... Global Advancements, Business Models, Technology Roadmap, Forecasts and ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... Effect was especially strong for estrogen-sensitive tumor types, study ... consumed even in small amounts, increases the risk of ... cancer, a new study shows. , The findings, expected ... the American Association for Cancer Research, in San Diego, ...
... (p. 46). Senior Editor David J. Jefferson writes,about the ... Ulysses S.,Grant High School, class of ,82 as part ... former classmates, Jefferson tells the,stories of those who lived ... the first for which divorce was just another part ...
... attacks in their tracks , , SATURDAY, April 12 (HealthDay ... for millions of Americans. , With a bit ... their suffering or perhaps even avoid it altogether, according ... of allergy and clinical immunology at the Saint Louis University ...
... Care, MILLBRAE, Calif., April 11 Healthcare ... second strike at,the facility in two months, in ... workers, proposals to improve care., The three-day ... on Tuesday, April 15.,Caregivers launched a previous, 24-hour ...
... paid but more upset when they owned stock , , ... clinical studies aren,t overly concerned if researchers have financial ... a U.S. study. , "Though peoples, willingness to take ... substantially based on the types of financial disclosures, and ...
... Puerto Ricans have higher rates of depression than other ... new study by researchers at Hebrew SeniorLifes Institute for ... Ricans, who make up 11 percent of the Hispanics ... depression, compared to Mexican Americans, Cuban Americans, and Hispanics ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Spring and Pollen Are in the Air 2Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2Health News:Researchers find disparities in depression among older Hispanics in US 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: